Comparative study of topical 5-aminolevulinic acid photodynamic therapy (5-ALA-PDT) and surgery for the treatment of high-grade vaginal intraepithelial neoplasia

Zhang, Yingcui; Su, Yuehui; Tang, Yujie; Qin, Lianjie; Shen, Yan; Wang, Bingjie; Zhou, Mengjiao; Zhou, Yingying; Cao, Liang; Zhang, Ting; Zhang, Mengzhen

doi:10.1016/j.pdpdt.2022.102958

Cited by 14 publications

(11 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(A) 5-aminolevulinic acid: ALA is a photosensitizer employed in PDT for cervical cancer. 67 Several clinical trials have assessed the safety and efficacy of ALA-PDT in patients with CIN ( Tables 4 and 5 ). Additional clinical studies are necessary to evaluate the long-term effectiveness of ALA-PDT in cervical cancer treatment.…”

Section: Discussionmentioning

confidence: 99%

“…(C) Photofrin: A photosensitizer approved for use in PDT for multiple cancers, including cervical cancer. 67 Additional clinical studies are needed to assess the long-term effectiveness of photofrin-mediated PDT in treating cervical cancer.…”

Section: Discussionmentioning

confidence: 99%

“…(D) Hexaminolevulinate: A photosensitizer employed in PDT for different cancers, including cervical cancer. 67 Further clinical studies are necessary to evaluate the long-term efficacy of hexaminolevulinate-mediated PDT in cervical cancer treatment.…”

Section: Discussionmentioning

confidence: 99%

“…(F) Zinc phthalocyanine: A photosensitizer that can be utilized in PDT for cervical cancer. 67 It exhibits high absorption in the red-light region, making it effective for PDT. When exposed to light at a specific wavelength, the photosensitizer generates reactive oxygen species capable of destroying cancer cells.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Photodynamic therapy of cervical cancer: a scoping review on the efficacy of various molecules

Shanazarov,

Zare,

Mussin

et al. 2024

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Background: Cervical cancer poses a considerable worldwide health issue, where infection with the human papillomavirus (HPV) plays a vital role as a risk factor. Photodynamic therapy (PDT) is a minimally invasive treatment for HPV-related cervical lesions, which uses photosensitizers and light to selectively destroy abnormal cells. Objectives: Our objective is to present a comprehensive overview of the different types of molecules employed in PDT to reduce the occurrence and fatality rates associated with cervical cancer. Design: Scoping review and bibliometric analysis. Methods: The article explores clinical trials investigating the efficacy of PDT in treating low-grade squamous intraepithelial lesion and high-grade squamous intraepithelial lesion, as well as preclinical approaches utilizing various molecules for PDT in cervical cancer. Furthermore, the article sheds light on potential molecules for PDT enhancement, examining their properties through computer modeling simulations, molecular docking, and assessing their advantages and disadvantages. Results: Our findings demonstrate that PDT holds promise as a therapeutic approach for treating cervical lesions associated with HPV and cervical cancer. Additionally, we observe that the utilization of diverse dye classes enhances the anticancer effects of PDT. Conclusion: Among the various molecules employed in PDT, functionalized fullerene exhibits a notable inclination toward overexpressed receptors in cervical cancer cells, making it a potential candidate for intensified use in PDT. However, further research is needed to evaluate its long-term effectiveness and safety.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Photodynamic therapy of cervical cancer: a scoping review on the efficacy of various molecules

Shanazarov,

Zare,

Mussin

et al. 2024

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

show abstract

“…In the case of persistent HR-HPV infection after hysterectomy, 5-Aminolevulinic acid PDT represents a safe, non-invasive, and effective option [ 52 ]. Studies have reported that the HR-HPV remission rate of PDT for VaIN after hysterectomy ranges from 41.9% to 93.3% [ 53 – 55 ]. Wang et al conducted a study on 163 patients with VAINI and HR-HPV infection, dividing them into two groups: the PDT group and the CO 2 laser group.…”

Section: Treatmentsmentioning

confidence: 99%

Comprehensive evaluation of vaginal intraepithelial neoplasia development after hysterectomy: insights into diagnosis and treatment strategies

Wei,

2024

Arch Gynecol Obstet

View full text Add to dashboard Cite

Vaginal intraepithelial neoplasia (VaIN), a precancerous lesion associated with human papillomavirus (HPV), impacts women’s health and quality of life. However, the natural progression of VaIN after hysterectomy remains uncertain, due to its low incidence. The existing literature predominantly consists of single-center retrospective studies lacking robust evidence-based medicine. The management of VaIN after hysterectomy is diverse and controversial, lacking a consensus on the optimal approach. Therefore, it is imperative to investigate the development of VaIN after hysterectomy, emphasizing the importance of accurate diagnosis and effective management strategies.

show abstract

HiPorfin photodynamic therapy for vaginal high-grade squamous intraepithelial lesion

Liu,

Wu,

et al. 2024

Arch Gynecol Obstet

View full text Add to dashboard Cite

Purpose We aimed to evaluate the efficacy and safety of HiPorfin-photodynamic therapy (PDT) in women with vaginal high-grade squamous intraepithelial Lesion (HSIL). Methods Retrospective analysis of eighteen patients with vaginal HSIL received HiPorfin-PDT between June 2019 and May 2023. Illumination with a 630-nm laser light was applied to the lesions 48–72 h after intravenous injection of 2 mg/kg HiPorfin®. The light dose to the lesions was 150 J/cm2. Results The mean age of the 18 patients was 45.8 years (range, 24 to 63). The complete response (CR) rate was 66.7% (12/18), 83.3% (15/18) and 83.3% (15/18) at 3, 6 and 12 months after PDT, respectively. Patients who achieved CR showed no signs of recurrence during long-term follow-up. There were three cases of persistent disease showing partial response (PR) and the lesion area was significantly reduced more than 50%. One patient with persistent disease then underwent thermocoagulation one time and subsequently showed no evidence of HSIL. Pre-treatment, 100% (18/18) patients were high-risk human papilloma virus (HR-HPV)-positive. HPV eradication rate was 16.7% (3/18), 22.2% (4/18) and 44.4% (8/18) after PDT at 3, 6 and 12 months, respectively. Before treatment, liquid-based cytology test ≥ atypical squamous cells of undetermined significance (ASCUS) was 94.4% (17/18). Negative conversion ratio of cytology was 47.1% (8/17), 52.9% (9/17) and 76.5% (13/17) at 3, 6 and 12 months, respectively. There were no serious adverse effects during and after PDT. Conclusions HiPorfin-PDT may be an effective alternative treatment for vaginal HSIL for organ-saving and sexual function protection.

show abstract

Comparative study of topical 5-aminolevulinic acid photodynamic therapy (5-ALA-PDT) and surgery for the treatment of high-grade vaginal intraepithelial neoplasia

Cited by 14 publications

References 26 publications

Photodynamic therapy of cervical cancer: a scoping review on the efficacy of various molecules

Photodynamic therapy of cervical cancer: a scoping review on the efficacy of various molecules

Comprehensive evaluation of vaginal intraepithelial neoplasia development after hysterectomy: insights into diagnosis and treatment strategies

HiPorfin photodynamic therapy for vaginal high-grade squamous intraepithelial lesion

Contact Info

Product

Resources

About